Company VALBIOTIS

Equities

ALVAL

FR0013254851

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for VALBIOTIS

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Euronext Paris Other stock markets 16:35:26 26/04/2024 BST			5-day change	1st Jan Change
3.9 ^EUR	-1.64%		+0.91%	-22.00%

04-26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. Valbiotis specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. Valbiotis is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases.

VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception Valbiotis has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.

Number of employees: 48

EUR in Million	2021	Weight	2022	Weight	Delta
Health Nutrition Products 100.0 %	0	100.0 %	1	100.0 %	+163.42%

EUR in Million	2021	Weight	2022	Weight	Delta
France 100.0 %	0	100.0 %	1	100.0 %	+163.42%

Managers	Title	Age	Since
Sebastien Peltier CEO	Chief Executive Officer	-	-
Pascal Sirvent CTO	Chief Tech/Sci/R&D Officer	-	31/08/17
Sébastien Bessy COO	Chief Operating Officer	-	-
Murielle Cazaubiel CTO	Chief Tech/Sci/R&D Officer	-	30/09/18
Jean Zetlaoui		-	-
Charlotte Jezequel HRO	Human Resources Officer	-	31/12/12

Members of the board	Title	Age	Since
Agnès Tixier BRD	Director/Board Member	-	17/03/19
Laurent Lévy CHM	Chairman	53	28/02/17
Sebastien Peltier CEO	Chief Executive Officer	-	-
Sébastien Bessy COO	Chief Operating Officer	-	-
Jean Zetlaoui BRD	Director/Board Member	-	25/10/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,424,918	11,366,315 ( 91.48 %)	16,057 ( 0.1292 %)	91.48 %

Name	Equities	%	Valuation
Sebastien Peltier 3.999 %	631,550	3.999 %	2 M €
OFI Invest Asset Management SA 3.802 %	600,467	3.802 %	2 M €
Amiral Gestion SA 2.831 %	447,214	2.831 %	2 M €
Talence Gestion SAS 0.8861 %	139,960	0.8861 %	548 699 €
Friedland Gestion SAS 0.7774 %	122,781	0.7774 %	481 351 €
Vatel Capital SAS 0.5712 %	90,222	0.5712 %	353 706 €
Karakoram SAS 0.5187 %	81,924	0.5187 %	321 175 €
Hermitage Gestion Privée SA 0.5065 %	80,000	0.5065 %	313 632 €
Financière Arbevel SA 0.5064 %	79,985	0.5064 %	313 573 €
Pure Capital SA 0.2839 %	44,843	0.2839 %	175 802 €

Name	Equities	%	Valuation
VALBIOTIS 0.11%	17,819	0.11%	69,858 $

Valbiotis SA

12F rue Paul VATINE

17180, Perigny

+33 5 46 28 62 58

http://www.valbiotis.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.9 EUR

Average target price

10.07 EUR

Spread / Average Target

+158.12%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VALBIOTIS	-22.00%	65.67M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs